Clinical outcomes of the drugs repurposed for the treatment of COVID-19
- Nitin Tandon,
- Vijay Luxami,
- Runjhun Tandon,
- Kamaldeep Paul
Vijay Luxami
Thapar Institute of Engineering and Technology
Author ProfileKamaldeep Paul
Thapar Institute of Engineering and Technology
Author ProfileAbstract
SARS-CoV-2 infections are the most contagious among the three
coronavirus infections the world has witnessed till date which have
affected almost all parts of the world in millions of population till
date since its outbreak in china in Dec. 2019. Moreover, it has severely
hit the world economy and therefore there is a dire need to develop the
treatment of this deadly disease. Numbers of potential vaccines are in
the early or advanced stage of clinical trials. But the development of a
vaccine is a very tedious and time consuming task. Therefore, numbers of
groups are working on the repurposing of drugs with already known safety
and efficacy profile to shorten the time of development of the potential
treatment. The main aim of this review article is to summarize the
clinical outcomes of the various drugs which have been repurposed for
the treatment of COVID-19 associated with SARS-CoV-2.